what backs bitcoin, searches

Jinmo Technology: The reserve price for the transfer of 40% equity of Mo Tian Jun Fu is 9,980,600 yuan. Jinmo Technology announced that the company held the 28th meeting of the 4th Board of Directors on November 29th, 2024, and reviewed and approved the Proposal on Authorizing the General Manager's Office to Transfer the Equity of Joint Venture. Authorized by the resolution of the board of directors, the company entrusted Southwest United Assets and Equity Exchange to publicly list and transfer 40% equity of Beijing Mo Tian Jun Fu Private Equity Fund Management Co., Ltd., with a reserve price of 9,980,600 yuan. Aerofilm Technology Development Group Co., Ltd. became the final transferee, with a transaction price of 9,980,600 yuan. Aerofilm Technology holds 23.63% shares of Jinmo Technology, which is the controlling shareholder of the company and also the shareholder holding more than 5% shares. This transaction constitutes a connected transaction.The OpenAI webpage shows that API, ChatGPT and Sora are all running normally.Hebang Bio established a mining engineering company in Leshan, Sichuan. The enterprise search APP shows that Leshan Hebang Mining Engineering Co., Ltd. was established recently, with Fei Wang as the legal representative and a registered capital of 10 million yuan. Its business scope includes: mineral resources reserve evaluation service; Mineral resources reserve estimation and report preparation services; Geological disaster management services, etc. Enterprise investigation shows that the company is wholly owned by Hebang Bio.

Japan's Shimane nuclear power plant operating company said that there was no abnormality in the reactor water level gauge of Unit 2, which was previously misjudged. On December 12, local time, China Electric Power Company of Japan conducted an investigation on the report that the reactor water level gauge of Unit 2 of Shimane nuclear power plant was once abnormal, and the results showed that there was no abnormality. The company said that the value displayed by the instrument was normal, but the operator misunderstood the data and misjudged it as abnormal. (CCTV News)Nordic United Bank: The risk of the European Central Bank cutting interest rates by 50 basis points cannot be ignored. Nordic United Bank said that the European Central Bank may cut interest rates by 25 basis points again, but there is also a significant risk of cutting interest rates by 50 basis points. The differences within the Committee have intensified again, and it is not easy for Lagarde to get another consistent compromise. A possible compromise is to cut interest rates by 25 basis points, and at the same time, some guidelines are given, indicating that as long as the ECB's benchmark view remains unchanged, it may cut interest rates again in January. Our benchmark expectation is still to cut interest rates by 25 basis points before the meeting in April next year, when the deposit interest rate is expected to reach 2.25%.Qianjin Pharmaceutical Co., Ltd.: The subsidiary company obtained the dapoxetine hydrochloride Pharmaceutical Registration Certificate, and Qianjin Pharmaceutical announced that Qianjin Xiangjiang Pharmaceutical Co., Ltd. received the dapoxetine hydrochloride Pharmaceutical Registration Certificate approved and issued by National Medical Products Administration. The medicine is suitable for the treatment of male premature ejaculation patients aged 18 to 64.

South Korea's National Assembly passed "Yin Xiyue's General Special Inspection Law" and "Jin Jianxit's Inspection Law". The reporter of the General Station was informed that on the 12th local time, South Korea's National Assembly held a general meeting of parliamentarians and passed "Yin Xiyue's General Special Inspection Law" and "Jin Jianxit's Inspection Law". (CCTV News)Schlegel, Governor of Swiss National Bank: If monetary policy needs to be further relaxed, interest rate reduction is still the main tool. The Swiss National Bank is still willing to intervene in the foreign exchange market when necessary.Mengke Pharmaceutical Co., Ltd.: The new packaging of Contizontamide tablets will be on the market soon. Mengke Pharmaceutical Co., Ltd. announced that the company has launched Contizontamide tablets with new packaging specifications, and a box of 12 tablets will be on the market soon. Contizontamide tablet is a new class 1 oxazolidinone antibacterial drug with global intellectual property rights. It was approved by National Medical Products Administration, China on June 1st, 2021 for the treatment of complex skin and soft tissue infections.